Coronavirus company news summary – BD receives additional orders for 177 million injection devices – AXIM develops Covid-19 test for neutralising antibodies

22 July 2020 (Last Updated July 22nd, 2020 09:07)

ndd Medical Technologies has launched single patient-use, inline filters for its lung function testing devices. The filters are expected to offer additional safety amid the Covid-19 pandemic. The filters complement the EasyOne spirometry range, which includes the EasyOne Air, Pro, and Pro LAB.

BD has received additional orders for needles and syringes from the US and Canada that totals 177 million injection devices. In total, the company has received orders of 330 million needles and syringes from the US, Canada and the UK. Most of the orders are expected to be delivered by the end of this year, in expectation of the vaccine being approved later this year or early next year.

Medical Marijuana has announced that its investment company AXIM Biotechnologies has developed a rapid diagnostic test that measures the levels of functional neutralising antibodies that are said to prevent SARS-CoV-2 (Covid-19) infection. AXIM’s test takes ten minutes and measures the certain subpopulation of antibodies to prevent the coronavirus from attacking the body. The company has submitted the application for pre-Emergency Use Authorisation (EUA) with the US Food and Drug Administration (FDA).

PerkinElmer has launched a dry blood spot (DBS) based test for SARS-CoV-2 IgG that uses its GSP/DELFIA platform that enables the processing of around 5,000 samples daily. The test is marketed as a CE-IVD test and PerkinElmer aims to submit its application to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA).